Eugene Ruzagira

Entebbe, C, Uganda

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 71 publications

Persistent gaps in the prevention of mother-to-child HIV transmission in central Uganda: a case-control study.

Persistent gaps in the prevention of mother-to-child HIV transmission in central Uganda: a case-control study.

Journal: International health
Published: May 17, 2026

Knowledge, perceptions, uptake, and determinants of HPV vaccination, and preferred delivery strategies among out-of-school girls in Masaka, Uganda.

Knowledge, perceptions, uptake, and determinants of HPV vaccination, and preferred delivery strategies among out-of-school girls in Masaka, Uganda.

Journal: Human vaccines & immunotherapeutics
Published: April 03, 2026

High HIV incidence among HIV infected BUT undetected individuals seeking HIV voluntary counselling and testing services in the greater Masaka Region in Uganda.

High HIV incidence among HIV infected BUT undetected individuals seeking HIV voluntary counselling and testing services in the greater Masaka Region in Uganda.

Journal: Journal of acquired immune deficiency syndromes (1999)
Published: February 02, 2026

A Comparison of F/TAF and F/TDF as HIV Pre-Exposure Prophylaxis in a Predominantly Cisgender Women Population in East and South Africa: A Randomized, Factorial, Noninferiority Trial.

A Comparison of F/TAF and F/TDF as HIV Pre-Exposure Prophylaxis in a Predominantly Cisgender Women Population in East and South Africa: A Randomized, Factorial, Noninferiority Trial.

Journal: Journal of acquired immune deficiency syndromes (1999)
Published: September 01, 2025

Who is a mobile man 'at risk'? Masculinity, work-related mobility, and HIV-related risks in Uganda and South Africa.

Who is a mobile man 'at risk'? Masculinity, work-related mobility, and HIV-related risks in Uganda and South Africa.

Journal: Journal of migration and health
Published: August 12, 2025

Counterfactual Groups to Assess Vaccine or Treatment Efficacy in HIV Prevention Trials in High-Risk Populations in Uganda.

Counterfactual Groups to Assess Vaccine or Treatment Efficacy in HIV Prevention Trials in High-Risk Populations in Uganda.

Journal: Vaccines
Published: June 23, 2025

Evaluating adherence in an active-controlled HIV pre-exposure prophylaxis trial (PrEPVacc) to inform the estimation of HIV incidence in a counterfactual placebo arm.

Evaluating adherence in an active-controlled HIV pre-exposure prophylaxis trial (PrEPVacc) to inform the estimation of HIV incidence in a counterfactual placebo arm.

Journal: HIV research & clinical practice
Published: June 11, 2025

The impact of the COVID-19 pandemic on healthy volunteer motivations: a mixed-methods study of participants in plague vaccine trials in the UK and Uganda.

The impact of the COVID-19 pandemic on healthy volunteer motivations: a mixed-methods study of participants in plague vaccine trials in the UK and Uganda.

Journal: BMC public health
Published: May 13, 2025

"Resilience amidst challenges": Healthcare users' experiences of access and utilisation of primary healthcare services during the COVID-19 pandemic in southwestern Uganda.

"Resilience amidst challenges": Healthcare users' experiences of access and utilisation of primary healthcare services during the COVID-19 pandemic in southwestern Uganda.

Journal: PLOS global public health
Published: May 08, 2025

An early functional adaptive NK cell signature drives optimal CD8 + T-cell activation and predicts sustained HIV-1 viral control.

An early functional adaptive NK cell signature drives optimal CD8 + T-cell activation and predicts sustained HIV-1 viral control.

Journal: bioRxiv : the preprint server for biology
Published: April 01, 2025

Efficacy and Safety of Long-acting Injectable Cabotegravir and Rilpivirine in Improving HIV-1 Control in sub-Saharan Africa: Protocol for a Phase 3b Open-Label Randomized Controlled Trial (IMPALA).

Efficacy and Safety of Long-acting Injectable Cabotegravir and Rilpivirine in Improving HIV-1 Control in sub-Saharan Africa: Protocol for a Phase 3b Open-Label Randomized Controlled Trial (IMPALA).

Journal: Wellcome open research
Published: March 20, 2025

Safety and Immunogenicity of a Modified Self-Amplifying Ribonucleic Acid (saRNA) Vaccine Encoding SARS-CoV-2 Spike Glycoprotein in SARS-CoV-2 Seronegative and Seropositive Ugandan Individuals.

Safety and Immunogenicity of a Modified Self-Amplifying Ribonucleic Acid (saRNA) Vaccine Encoding SARS-CoV-2 Spike Glycoprotein in SARS-CoV-2 Seronegative and Seropositive Ugandan Individuals.

Journal: Vaccines
Published: March 17, 2025
Showing 1-12 of 71

Last Updated: 09/26/2026